Kintara Therapeutics, Inc.

  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
    • Academic Collaborations
    • Advisors
  • Pipeline
    • Overview
    • VAL-083
    • REM-001
  • Clinical Trials
  • News & Media
    • Press Releases
    • Publications and Abstracts
    • Presentations
    • Recent News
    • Events
  • Investors
    • Overview
    • Analyst Coverage
    • News / Events
    • Company Information
    • Stock Data
    • SEC Filings
    • Corporate Governance
  • Contact
  • Careers

Press Releases

News & Media

News & Media

  • Press Releases
  • Publications and Abstracts
  • Presentations
  • Recent News
  • Events

Kintara Therapeutics Provides Positive Site Activation Update on GCAR Phase 2/3 Clinical Trial for Glioblastoma

Aug 17, 2021

Kintara Therapeutics to Present at the Investor Summit Virtual Conference on August 17, 2021

Aug 12, 2021

Kintara Therapeutics to Present at the BTIG Virtual Biotechnology Conference on August 9, 2021

Aug 4, 2021

Kintara Reports Topline Results From Phase 2 Clinical Trial of VAL-083 for Recurrent GBM

Jul 1, 2021

Kintara Therapeutics Set to Join Russell Microcap® Index

Jun 7, 2021

Kintara Therapeutics Enrolls Final Patient in Phase 2 Clinical Trial of VAL-083 for Adjuvant Treatment of Brain Tumors

Jun 3, 2021

Kintara Therapeutics to Present at the LD Micro Virtual Invitational Conference on June 9, 2021

Jun 2, 2021

Kintara Therapeutics Provides Positive Site Activation Update on GCAR Phase 2/3 Clinical Trial for Glioblastoma

May 26, 2021

Kintara Therapeutics Announces Fiscal Third Quarter 2021 Financial Results and Provides Corporate Update

May 14, 2021

Kintara Therapeutics to Participate at the Benzinga Global Small Cap Conference

May 5, 2021
    • 1
    • 2
    • 3
    • 4
    • 5
    • 6
    • 7
    • 8
    • 9
    • 10
    • ...34
    © 2023 Kintara Therapeutics, Inc. All Rights Reserved.
    Privacy Policy Disclaimer Sitemap Legal Information Manage Cookie Preferences